FMRFamide-like peptides encoded on the flp-18 precursor gene activate two isoforms of the orphan Caenorhabditis elegans G-protein-coupled receptor Y58G8A.4 heterologously expressed in mammalian cells

Teresa M Kubiak,Martha J Larsen,Jerry W Bowman,Timothy G Geary,David E Lowery
DOI: https://doi.org/10.1002/bip.20850
Biopolymers
Abstract:Two alternatively spliced variants of an orphan Caenorhabditis elegans G-protein-coupled receptors (GPCRs; Y58G8A.4a and Y58G8A.4b) were cloned and functionally expressed in Chinese hamster ovary (CHO) cells. The Y58G8A.4a and Y58G8A.4b proteins (397 and 433 amino acid residues, respectively) differ both in amino acid sequence and length of the C-terminal tail of the receptor. A calcium mobilization assay was used as a read-out for receptor function. Both receptors were activated, with nanomolar potencies, by putative peptides encoded by the flp-18 precursor gene, leading to their designation as FLP-18R1a (Y58G8A.4a) and FLP-18R1b (Y58G8A.4b). Three Ascaris suum neuropeptides AF3, AF4, and AF20 all sharing the same FLP-18 C-terminal signature, -PGVLRF-NH(2), were also potent agonists. In contrast to other previously reported C. elegans GPCRs expressed in mammalian cells, both FLP-18R1 variants were fully functional at 37 degrees C. However, a 37 to 28 degrees C temperature shift improved their activity, an effect that was more pronounced for FLP-18R1a. Despite differences in the C-terminus, the region implicated in distinct G-protein recognition for many other GPCRs, the same signaling pathways were observed for both Y58G8A.4 isoforms expressed in CHO cells. Gq protein coupling seems to be the main but not the exclusive signaling pathway, because pretreatment of cells with U-73122, a phospholipase inhibitor, attenuated but did not completely abolish the Ca(2+) signal. A weak Gs-mediated receptor activation was also detected as reflected in an agonist-triggered concentration-dependent cAMP increase. The matching of the FLP-18 peptides with their receptor(s) allows for the evaluation of the pharmacology of this system in the worm in vivo.
What problem does this paper attempt to address?